Lexaria Bioscience announced that study program DIAB-A22-1 is expected to begin on schedule. This is Lexaria’s first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol, or CBD, may potentially have therapeutic utility against diabetes. Lexaria has previously evidenced the safety and efficacy of DehydraTECH-CBD in human hypertension studies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LEXX: